VentriPoint Financial Statements From 2010 to 2026
| VPTDF Stock | USD 0.1 0.01 5.00% |
Check VentriPoint Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VentriPoint Diagnostics' main balance sheet or income statement drivers, such as , as well as many indicators such as . VentriPoint financial statements analysis is a perfect complement when working with VentriPoint Diagnostics Valuation or Volatility modules.
VentriPoint |
VentriPoint Diagnostics Company Return On Equity Analysis
VentriPoint Diagnostics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current VentriPoint Diagnostics Return On Equity | -1.35 |
Most of VentriPoint Diagnostics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VentriPoint Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, VentriPoint Diagnostics has a Return On Equity of -1.3501. This is 94.37% lower than that of the Healthcare sector and 84.53% lower than that of the Medical Devices industry. The return on equity for all United States stocks is notably higher than that of the company.
VentriPoint Diagnostics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining VentriPoint Diagnostics's current stock value. Our valuation model uses many indicators to compare VentriPoint Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across VentriPoint Diagnostics competition to find correlations between indicators driving VentriPoint Diagnostics's intrinsic value. More Info.VentriPoint Diagnostics is rated fourth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the VentriPoint Diagnostics' earnings, one of the primary drivers of an investment's value.About VentriPoint Diagnostics Financial Statements
VentriPoint Diagnostics stakeholders use historical fundamental indicators, such as VentriPoint Diagnostics' revenue or net income, to determine how well the company is positioned to perform in the future. Although VentriPoint Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in VentriPoint Diagnostics' assets and liabilities are reflected in the revenues and expenses on VentriPoint Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in VentriPoint Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company was incorporated in 2004 and is based in Toronto, Canada. Ventripoint Diagnostics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in VentriPoint Pink Sheet
VentriPoint Diagnostics financial ratios help investors to determine whether VentriPoint Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VentriPoint with respect to the benefits of owning VentriPoint Diagnostics security.